Objective: To obtain complete DNA sequences of adenoviral (AdV) D8 genome from patients with conjunctivitis and determine the relation of sequence variation to clinical outcomes.
Design: This study is a post hoc analysis of banked conjunctival swab samples from the BAYnovation Study, a previously conducted, randomized controlled clinical trial for AdV conjunctivitis.
Participants: Ninety-six patients with AdV D8-positive conjunctivitis who received placebo treatment in the BAYnovation Study were included in the study.
Purpose: To determine the characteristics of conjunctivitis associated with human adenovirus E4 (AdV E4).
Methods: Samples and outcomes from 500 patients with conjunctivitis were obtained from the NVC-422 randomized controlled clinical trial comparing auriclosene to placebo. Molecular typing identified 36 cases associated with AdV E4.
Grassland environments face a number of threats including land use change, changing climate and encroachment of woody plants. In the Southern Plains of the United States, woody plant encroachment threatens traditional agricultural grazing economies in addition to grassland dependent wildlife species. Numerous studies have examined the physical drivers of conversion from grassland to woodland but social drivers may be equally important to understanding the causes of and prescriptions for environmental degradation.
View Article and Find Full Text PDFMechanically guided, 3D assembly has attracted broad interests, owing to its compatibility with planar fabrication techniques and applicability to a diversity of geometries and length scales. Its further development requires the capability of on-demand reversible shape reconfigurations, desirable for many emerging applications (e.g.
View Article and Find Full Text PDFPurpose: To determine host and pathogen factors predictive of outcomes in a large clinical cohort with keratoconjunctivitis.
Design: Retrospective analyses of the clinical and molecular data from a randomized, controlled, masked trial for auricloscene for keratoconjunctivitis (NVC-422 phase IIB, NovaBay; clinicaltrials.gov identifier, NCT01877694).